Mounjaro (tirzepatide) is a first-in-class dual GIP/GLP-1 receptor agonist the only medication that targets two key metabolic hormones simultaneously. Marketed as Zepbound for weight management, it has shown the most significant weight loss results in clinical trials.
Book a Free Consultation
Mounjaro is the only dual GIP/GLP-1 receptor agonist available. By targeting two metabolic hormones instead of one, it has demonstrated the most significant weight loss results in clinical trials up to 22.5% of body weight.
They contain the same active ingredient (tirzepatide). Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved specifically for weight management. Your physician will prescribe the appropriate version.
Clinical trials suggest tirzepatide produces more significant weight loss than semaglutide, likely due to its dual-receptor mechanism. However, the best medication for you depends on your individual health profile.
Similar to other GLP-1 medications primarily gastrointestinal effects like nausea, diarrhea, and decreased appetite. These typically improve over time and with dose titration. Your Vitelize physician manages these carefully.
Coverage varies by plan and indication. Mounjaro may be covered for type 2 diabetes. Zepbound coverage for weight management is expanding. Your Vitelize team helps navigate your specific insurance options.
Absolutely and Vitelize strongly recommends it. The muscle preservation benefits of resistance training are especially important with tirzepatide, given its more significant weight loss effects.
Tirzepatide carries a boxed warning for thyroid C-cell tumors. Contraindicated in patients with MTC history or MEN2. Risks include pancreatitis, hypoglycemia, kidney injury, gallbladder disease, and serious allergic reactions. Not studied in patients with a history of pancreatitis. Discuss all medical conditions with your physician.
Take the 2-minute eligibility quiz. Free, no obligation.
Am I Eligible?